Abstract:Jianlan Peng, 1 Shiying Li, 2 Huihui Ti 1, 3 1 School of Chinese Materia Medica, Guangdong Pharmaceutical University, Guangzhou, People's Republic of China; 2 Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences and the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, People's Republic of China; 3 Guangdong Province Precise Medicine and Big Data Engineering Technology Research Center for Traditional Chinese Medicine, Guangzhou, People's Republic of China Correspondence: Huihui Ti; Shiying Li, Email ; Low immunogenicity of tumors poses a challenge in the development of effective tumor immunotherapy. However, emerging evidence suggests that certain therapeutic approaches, such as chemotherapy, radiotherapy, and phototherapy, can induce varying degrees of immunogenic cell death (ICD). This ICD phenomenon leads to the release of tumor antigens and the maturation of dendritic cells (DCs), thereby enhancing tumor immunogenicity and promoting immune responses. However, the use of a single conventional ICD inducer often fails to achieve in situ tumor ablation and establish long-term anti-tumor immune responses. Furthermore, the induction of ICD induction varies among different approaches, and the distribution of the therapeutic agent within the body influences the level of ICD and the occurrence of toxic side effects. To address these challenges and further boost tumor immunity, researchers have explored nanosystems as inducers of ICD in combination with tumor immunotherapy. This review examines the mechanisms of ICD and different induction methods, with a specific focus on the relationship between ICD and tumor immunity. The aim is to explore the research advancements utilizing various nanomaterials to enhance the body's anti-tumor effects by inducing ICD. This paper aims to contribute to the development and clinical application of nanomaterial-based ICD inducers in the field of cancer immunotherapy by providing important theoretical guidance and practical references. Keywords: tumor immunotherapy, immunogenicity, ICD, DAMPs, nanosystems The advent of malignant tumors poses a considerable threat to human society. Traditional treatments including surgery, radiotherapy and chemotherapy, often exhibit limitations in achieving complete tumor eradication or yield unfavorable prognoses due to tumor cell tolerance and recurrence. Immunotherapy, an emerging field in antineoplastic medicine, has revolutionised cancer treatment. It utilises various approaches, including immune checkpoint inhibitors (ICIs), lymphocyte activating factors, chimeric antigen receptor (CAR)-T cells, other cells, cancer vaccines, lysosomal viruses, and bispecific antibodies. Cancer immunotherapy is a significant milestone in cancer treatment. 1,2 In 2011, the antibody ipilimumab, targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), was approved. Additionally, in 2014, pembrolizumab and nivolumab, both antibodies blocking programmed cell death protein 1 (anti-PD-1) and its ligand 1 (anti-PD-L1), were also approved. 3 However, the low response rate seen in most patients on treatment results in the emergence of immune-related adverse side effects such as cytokine storm, myocarditis and neurotoxicity, which can be fatal due to off-target distribution of ICIs. 4 Hyporesponsiveness to ICIs can be attributed to the "cold tumour" of most tumour patients, including inadequate antigen presentation and an immunosuppressive microenvironment. Therefore, activation to enhance tumour immunogenicity has become a key focus of tumour immunotherapy in this field. 5 Substantial evidence has demonstrated that various tumor immunotherapies, encompassing chemotherapy, radiation therapy, phototherapy, sonic therapy, chemodynamic therapy, ablation treatment, high hydrostatic pressure (HHP), or oncolytic virus (OVs), can elicit Immunogenic cell death (ICD) under specific conditions. This process leads to the release of tumor-associated antigens (TAA) and tumor-specific antigens (TSA), along with the exposure of damage-associated molecular patterns (DAMPs) (Figure 1). Upon release, TAA are typically phagocytosed by antigen-presenting cells (APCs), particularly dendritic cells (DCs), and subsequently presented to T cells. 6 Concurrently, DAMPs facilitate DC maturation, activate cytotoxic T lymphocytes (CTLs), and stimulate the secretion of various pro-inflammatory cytokines associated with innate and adaptive immunity, such as IFN-γ, TNF-α, IL-6, and IL-1β. This orchestrated cascade of events ultimately induces a robust immune response. The activation of anti-tumor T cells and the release of cytok -Abstract Truncated-

Biomaterials That Induce Immunogenic Cell Death

Bimetallic Peroxide-Based Nanotherapeutics for Immunometabolic Intervention and Induction of Immunogenic Cell Death to Augment Cancer Immunotherapy

Consensus guidelines for the detection of immunogenic cell death.

Nanomaterials: leading immunogenic cell death-based cancer therapies

Immunogenic Cell Death in Cancer Therapy: Present and Emerging Inducers

Cancer Immunotherapy Elicited by Immunogenic Cell Death Based on Smart Nanomaterials

Immunogenic cell death inducers for enhanced cancer immunotherapy

Immunogenic cell death-based cancer vaccines: promising prospect in cancer therapy

Targeting immunogenic cell death in cancer

Plant-derived natural compounds: A new frontier in inducing immunogenic cell death for cancer treatment

Clinical application of immunogenic cell death inducers in cancer immunotherapy: turning cold tumors hot

Sensitize Tumor Immunotherapy: Immunogenic Cell Death Inducing Nanosystems

Mechanisms of immunogenic cell death and immune checkpoint blockade therapy

Chemotherapeutic and targeted drugs-induced immunogenic cell death in cancer models and antitumor therapy: An update review

Immunogenic Cell Death in Cancer Therapy

Immunogenic Cell Death Induction by Ionizing Radiation

Stimuli-responsive nanodelivery systems for amplifying immunogenic cell death in cancer immunotherapy

Natural compound inducers of immunogenic cell death

Local Drug Delivery Techniques for Triggering Immunogenic Cell Death

Immunogenic Cell Death Activates the Tumor Immune Microenvironment to Boost the Immunotherapy Efficiency

Current status of nanoparticle-mediated immunogenic cell death in cancer immunotherapy